Your browser doesn't support javascript.
loading
Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases.
Wilmott, James S; Tawbi, Hussein; Engh, Johnathan A; Amankulor, Nduka M; Shivalingam, Brindha; Banerjee, Hiya; Vergara, Ismael A; Lee, Hansol; Johansson, Peter A; Ferguson, Peter M; Saiag, Philippe; Robert, Caroline; Grob, Jean-Jacques; Butterfield, Lisa H; Scolyer, Richard A; Kirkwood, John M; Long, Georgina V; Davies, Michael A.
Afiliação
  • Wilmott JS; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
  • Tawbi H; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Engh JA; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.
  • Amankulor NM; The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Shivalingam B; The University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Banerjee H; The University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Vergara IA; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
  • Lee H; Department of Neurosurgery, Royal Prince Alfred Hospital, New South Wales, Australia.
  • Johansson PA; Novartis Pharmaceuticals Corporation, Basel, Switzerland.
  • Ferguson PM; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
  • Saiag P; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Robert C; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.
  • Grob JJ; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
  • Butterfield LH; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Scolyer RA; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.
  • Kirkwood JM; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
  • Davies MA; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia.
Clin Cancer Res ; 29(3): 521-531, 2023 02 01.
Article em En | MEDLINE | ID: mdl-36477181
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Neoplasias Encefálicas / Melanoma Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Neoplasias Encefálicas / Melanoma Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article